Sobi hires Alan Raffensperger as COO
This article was originally published in Scrip
Swedish Orphan Biovitrum has appointed Alan Raffensperger chief operating officer. Mr Raffensperger was most recently CEO of Benechill, a US-based medical device company. Prior to that, he served as executive director and head of nephrology at Amgen. He will report to CEO Geoffrey McDonough.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.